GlassScriptPhysician profile
Vincent Sami Petros
NPI 1134539729
$7,455.07
in general payments reported to CMS, 2019-2025
29 companies · $1,741 in 2025
The $1,741 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $581 · 2022: $1,260 · 2023: $1,587 · 2024: $2,286 · 2025: $1,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,530 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,530.29 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,309.33 | 2021-2025 | |
| Janssen Biotech, INC. | $1,044.36 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $801.64 | 2021-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $501.07 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $472.83 | 2021-2024 | Xifaxan, Trulance, Relistor |
| Lilly USA, LLC | $332.26 | 2023-2025 | Omvoh |
| Celgene Corporation | $229.99 | 2021-2024 | Zeposia |
| Organon LLC | $199.28 | 2021-2023 | Hadlima, Renflexis |
| Qol Medical, LLC | $169.29 | 2021-2025 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $162.10 | 2021-2024 | Zeposia |
| Genzyme Corporation | $149.44 | 2022-2025 | |
| Cook Medical LLC | $137.54 | 2023 | Echotip |
| Boston Scientific Corporation | $131.87 | 2021-2025 | Cre Pro |
| Ironwood Pharmaceuticals, INC | $122.01 | 2022-2025 | Linzess |
| Madrigal Pharmaceuticals | $112.00 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $103.97 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $81.29 | 2024-2025 | Voquezna |
| Pfizer INC. | $59.28 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $56.46 | 2024-2025 | Vowst |
| Celltrion USA INC. | $55.19 | 2025 | Vegzelma |
| Olympus America INC. | $37.09 | 2024 | Endoclot Phs |
| Ipsen Biopharmaceuticals, INC | $33.53 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $33.09 | 2023-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $25.78 | 2021 | |
| Amgen INC. | $23.30 | 2022 | |
| Daiichi Sankyo INC. | $21.59 | 2022 | |
| Blueprint Medicines Corporation | $18.09 | 2025 | Ayvakit |
| Braintree Laboratories, INC. | $16.74 | 2023 | Suflave |
| Micro-Tech Endoscopy USA, INC. | $14.66 | 2025 | Lesionhunter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Petros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.